Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function indb/dbmice
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function indb/dbmice
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 170, Issue 3, Pages 519-531
Publisher
Wiley
Online
2013-06-11
DOI
10.1111/bph.12269
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
- (2013) Guntram Schernthaner et al. DIABETES CARE
- Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
- (2013) William N Washburn et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- Standards of Medical Care in Diabetes--2013
- (2012) DIABETES CARE
- New Experimental Models of Diabetic Nephropathy in Mice Models of Type 2 Diabetes: Efforts to Replicate Human Nephropathy
- (2012) María José Soler et al. Experimental Diabetes Research
- Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
- (2012) Vivian A. Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2012) Yoshihito Ohtake et al. JOURNAL OF MEDICINAL CHEMISTRY
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- (2012) Ele Ferrannini et al. Nature Reviews Endocrinology
- Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
- (2012) James J. Devenny et al. Obesity
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
- (2012) Yin Liang et al. PLoS One
- Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney
- (2011) Volker Vallon et al. Annual Review of Physiology
- TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity
- (2011) K Yamamoto et al. BRITISH JOURNAL OF PHARMACOLOGY
- SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
- (2011) Michael J. Jurczak et al. DIABETES
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Guidelines for reporting experiments involving animals: the ARRIVE guidelines
- (2010) JC McGrath et al. BRITISH JOURNAL OF PHARMACOLOGY
- Animal research: Reporting in vivo experiments: The ARRIVE guidelines
- (2010) Carol Kilkenny et al. BRITISH JOURNAL OF PHARMACOLOGY
- Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
- (2010) L. Zhang et al. DIABETES OBESITY & METABOLISM
- Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice
- (2010) Yi-Fei Dong et al. JOURNAL OF HYPERTENSION
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- SGLT2 inhibition — a novel strategy for diabetes treatment
- (2010) Edward C. Chao et al. NATURE REVIEWS DRUG DISCOVERY
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
- (2010) Jian Chen et al. Diabetes Therapy
- Goals of Treatment for Type 2 Diabetes: -Cell preservation for glycemic control
- (2009) P. Marchetti et al. DIABETES CARE
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice
- (2009) Kenji Katsuno et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cardiovascular and autonomic phenotype ofdb/dbdiabetic mice
- (2009) Danielle Senador et al. EXPERIMENTAL PHYSIOLOGY
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
- (2008) S. Han et al. DIABETES
- Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models
- (2008) Y. Fujimori et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The pathogenesis of diabetic nephropathy
- (2008) Suma Dronavalli et al. Nature clinical practice. Endocrinology & metabolism
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now